Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (UT1/UT2) Clinical Trial Not Allowed
ID: 347583Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $296K

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/347583

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-268.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine," aimed at supporting small business technology transfer (STTR) partnerships. This initiative focuses on the development of novel extracellular vesicle (EV)-based therapeutic platforms, addressing challenges related to large-scale manufacturing and production quality, which are critical for tissue and organ repair applications. The funding is essential for advancing therapeutic applications in regenerative medicine, with awards typically not exceeding $295,924 for Phase I and $1,972,828 for Phase II, and proposals must be submitted by June 6, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-268.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-268-Full-Announcement.html
    PAR-23-268.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has announced a funding opportunity aimed at the industrialization and translation of extracellular vesicles (EVs) for regenerative medicine. The funding supports small business technology transfer (STTR) partnerships focused on developing novel EV-based therapeutic platforms. The primary goals include addressing challenges such as large-scale manufacturing and production quality of EVs, which can facilitate tissue and organ repair. This initiative encourages proof-of-concept studies in Phase I and advancement to optimization in Phase II. A critical aspect of the program emphasizes compliance with Good Manufacturing Practices (GMP) and prioritizes applications that demonstrate significant commercialization potential. All proposals must adhere to specific guidelines and are subject to review based on criteria like significance, innovation, and feasibility. Eligible applicants consist of U.S. small business concerns, with awards usually not exceeding $295,924 for Phase I and $1,972,828 for Phase II. The funding opportunity is crucial for advancing therapeutic applications within the field of regenerative medicine, addressing ongoing challenges, and promoting innovative research solutions.
    Similar Opportunities
    Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Studies (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Studies (U01 Clinical Trial Not Allowed)" aimed at advancing research in regenerative medicine utilizing adult stem cells. This initiative, supported by the 21st Century Cures Act, encourages small businesses to develop collaborative projects that contribute to the field, although applications are not currently being solicited. With an estimated total program funding of $400,000, interested applicants should prepare for the upcoming Notice of Funding Opportunity (NOFO), with key dates including an estimated synopsis post date of August 1, 2025, and a close date of October 21, 2025. For further inquiries, potential applicants can contact Aron Marquitz, Ph.D., at aron.marquitz@nih.gov or by phone at 301-435-1240.
    Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator- Initiated Studies (UH3 Clincical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity titled "Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Studies," aimed at advancing research in regenerative medicine utilizing adult stem cells. This initiative, supported by the 21st Century Cures Act, encourages small businesses to develop collaborative projects, although applications are not currently being solicited. The funding will be provided through a cooperative agreement, with an estimated synopsis posting date of August 1, 2025, and a closing date for applications expected by October 21, 2025. For further inquiries, interested parties can contact Aron Marquitz, Ph.D., at aron.marquitz@nih.gov or by phone at 301-435-1240.
    Accelerating Product Excellence in Innovation and for Clinical Adoption (APEx) (U24 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Accelerating Product Excellence in Innovation and for Clinical Adoption (APEx)" through a cooperative agreement aimed at supporting the development of extramural Resource Centers (RCs) focused on tissue engineering and regenerative medicine (TE/RM). The initiative seeks to foster interdisciplinary translational projects (ITPs) that leverage clinical, scientific, and regulatory expertise to advance therapeutics, diagnostics, and monitoring solutions for tissue damage caused by various health conditions. This funding cycle is particularly significant as it aims to facilitate the validation and preclinical testing of promising TE/RM products, with the goal of achieving regulatory approvals for first-in-human studies. Interested applicants, particularly small businesses with relevant expertise, are encouraged to prepare for future applications, as the estimated synopsis post date is October 7, 2025, with a closing date of November 7, 2025, and an anticipated award date of July 1, 2026. For further inquiries, potential applicants can contact Dr. Scott Verbridge at scott.verbridge@nih.gov or by phone at 301-594-0676.
    Miniaturization and Automation of Tissue Chip Systems (MATChS) (UT1/UT2 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Miniaturization and Automation of Tissue Chip Systems (MATChS)" aimed at supporting Small Business Technology Transfer (STTR) applications. This initiative seeks to enhance microphysiological systems that replicate organ functions, focusing on the development of compact, automated systems for real-time analysis of tissue health to improve drug discovery and precision medicine. Eligible U.S.-based small businesses can apply for funding of up to $2.15 million for Phase I and Phase II awards, with proposals required to demonstrate innovation, a clear commercialization strategy, and collaboration with NIH staff. Interested applicants should refer to the full announcement available at NIH Grants and note that the application deadline is February 23, 2026.
    PHS 2025-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting eligible United States small business concerns (SBCs) to prepare applications for the PHS 2025-2 Omnibus Solicitation for Small Business Technology Transfer (STTR) Grant Applications, which includes Phase I, Phase II, Fast-Track, and Phase IIB grants. This opportunity aims to support innovative research and development projects that align with the NIH's mission, encouraging collaborations that leverage the technological expertise of small businesses in the health sector. The solicitation is contingent upon the reauthorization of the STTR program, with an estimated synopsis posting date of October 1, 2025, and a closing date of January 5, 2026. Interested applicants can reach out to the NIH SEED Office of Extramural Research at SEEDinfo@nih.gov or call 301-827-8595 for further information.
    NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)" aimed at supporting Small Business Concerns (SBCs) in conducting investigator-initiated exploratory clinical trials related to neurological disorders. This initiative encourages applications for Phase I and II studies focusing on drugs, biologics, devices, and therapies that align with the mission of the National Institute of Neurological Disorders and Stroke (NINDS), emphasizing the inclusion of a Plan for Enhancing Diverse Perspectives (PEDP) to foster innovation. The maximum funding amounts are $295,924 for Phase I and $1,972,828 for Phase II projects, with applications required to demonstrate readiness for eventual FDA regulatory approval. Interested applicants can begin submitting proposals on December 5, 2023, with the application deadline set for September 5, 2026; for further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Not Allowed) aimed at encouraging United States small business concerns (SBCs) to engage in research and development projects aligned with NIH's mission. Eligible applicants, defined as SBCs by the Small Business Administration, are invited to prepare for future submissions of Phase I, Phase II, Fast-Track, and Phase IIB grant applications, although applications are not currently being solicited. This funding opportunity is significant for fostering innovative health-related research and collaboration among small businesses and NIH institutes. Interested parties can reach out to the NIH SEED Office of Extramural Research at SEEDinfo@nih.gov or by phone at 301-827-8595 for further information, with the estimated synopsis posting date set for October 1, 2025, and a projected award date of June 1, 2026.
    Miniaturization and Automation of Tissue Chip Systems (MATChS) (U43/U44 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "Miniaturization and Automation of Tissue Chip Systems" (MATChS), aimed at advancing the development of automated and miniaturized microphysiological systems (MPS) for drug discovery and biomedical research. This funding opportunity encourages U.S. small business concerns (SBCs) to propose innovative solutions that enhance the efficiency and reliability of tissue chip technologies, with a focus on reducing complexity and costs while facilitating higher throughput. Approximately $2.15 million is allocated for FY 2024 to support projects that collaborate with NIH staff to achieve defined milestones and pathways to commercialization. Interested applicants must submit their proposals by February 23, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Engineering Improved Stem Cell-Derived Islet Cells for Replacement Therapies
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Engineering Improved Stem Cell-Derived Islet Cells for Replacement Therapies," aimed at advancing research in stem cell-derived islet cell products for enhanced cell replacement therapy outcomes. This initiative seeks to stimulate studies focused on engineering the inherent characteristics of these products, which are derived from well-defined cell bank sources, to improve graft viability and function, particularly in the context of type 1 diabetes. The estimated total program funding is $3 million, with approximately six awards expected, and interested applicants are encouraged to prepare collaborative proposals ahead of the anticipated Notice of Funding Opportunity (NOFO) release on August 1, 2025. For further inquiries, potential applicants can contact Dr. Albert J. Hwa at albert.hwa@nih.gov or by phone at 301-451-1525.
    Engineering Improved Stem Cell-Derived Islet Cells for Replacement Therapies (R01 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Engineering Improved Stem Cell-Derived Islet Cells for Replacement Therapies (R01 - Clinical Trial Not Allowed)" aimed at advancing research in the engineering of stem cell-derived islet cells specifically for Type 1 Diabetes therapies. This grant seeks to support studies that enhance the intrinsic characteristics of these islet cell products, which are derived from well-defined cell bank sources, to improve graft viability and function through optimized banking, manufacturing, and quality control processes. With an estimated total program funding of $3 million and an award ceiling of $500,000, the NIH anticipates awarding approximately six grants, with applications due by March 7, 2026. For further inquiries, interested applicants can contact Albert Hwa at NIDDKDEM@nih.gov.